NIH T32 Postdoctoral Research Training in Biotherapy of Cancer
compensatedJuly 1, 2021-University of Pittsburgh-Research Position for Surgical Residents
NIH T32 Postdoctoral Research Training in Biotherapy of Cancer
This training grant is a long-standing award from the National Cancer Institute of the National Institutes of Health (NIH) to the Division of Surgical Oncology at the University of Pittsburgh to provide eligible candidates with state-of-the-art basic research training in the biological therapy of cancer. The training period is for two years.
There are four areas of focused research interests: Immunotherapy, Autophagy/DAMP biology, Oncolytic/gene therapy, and targeted molecular therapy in cancer. The goal of this program is to prepare surgeons for a career as translational scientists in the field of biologic therapy of cancer. We will provide trainees with an immersive experience that will stress three core proficiencies necessary to be a successful translational scientist:
• Basic laboratory research skills
• Fundamental principles of clinical investigation
• Pragmatic experience in clinical trial management
At the completion of this training program the surgical trainee will be uniquely prepared to bridge the gap between clinical and laboratory research.
Eligibility: Candidates must have a MD or MD/PhD, be a categorical surgical resident or a surgical oncology fellow, have a strong interest in cancer research and a desire for an academic career in surgical oncology. Candidates need to possess integrity, perseverance, good communication skills, self-motivation, and strong recommendations. As stipulated by the granting agency, Candidate must be a US citizen or a US permanent resident.
The University of Pittsburgh is an Affirmative Action/Equal Opportunity Employer and values equality of opportunity, human dignity and diversity. EOE, including disability/vets